TSVT News & Events

Reports Q4 revenue $2.9M, consensus $13.03M. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma," said Chip Baird, chief executive officer, 2seventy bio. "This week marks four years since Abecma received FDA approval as the first anti-BCMA CAR T cell therapy approved for relapsed or refractory multiple myeloma. Together with BMS, we remain committed to expanding the reach of this important therapy. We launched 2seventy with the goal of providing more time to patients, and we believe with BMS' experience and resources, we can continue to improve outcomes for people living with multiple myeloma."

Medigene announced a $1M milestone payment from Regeneron was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy Bio's pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics of Regeneron's MAGE-A4 cell therapy, which contains a Medigene generated T cell receptor targeting MAGE-A4e